相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Correlation of PD-L1 Expression with Tumor Mutation Burden and Gene Signatures for Prognosis in Early-Stage Squamous Cell Lung Carcinoma
Hui Yu et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Tumor Mutation Burden and Efficacy of EGFR-Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Lung Cancers
Michael Offin et al.
CLINICAL CANCER RESEARCH (2019)
Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel
Zhijie Wang et al.
JAMA ONCOLOGY (2019)
Concurrent Driver Gene Mutations as Negative Predictive Factors in Epidermal Growth Factor Receptor-Positive Non-Small Cell Lung Cancer
Minjiang Chen et al.
EBIOMEDICINE (2019)
Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti-PD-(L)1 Therapies in Non-Small Cell Lung Cancer
Wenfeng Fang et al.
CLINICAL CANCER RESEARCH (2019)
Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial
Haruhiro Saito et al.
LANCET ONCOLOGY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Multiomics Prediction of Response Rates to Therapies to Inhibit Programmed Cell Death 1 and Programmed Cell Death 1 Ligand 1
Joo Sang Lee et al.
JAMA ONCOLOGY (2019)
Identification of genetic alterations associated with primary resistance to EGFR-TKIs in advanced non-small-cell lung cancer patients with EGFR sensitive mutations
Fang Wang et al.
CANCER COMMUNICATIONS (2019)
Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer
Matthew D. Hellmann et al.
CANCER CELL (2018)
Tumor Mutation Burden: Leading Immunotherapy to the Era of Precision Medicine?
Conor E. Steuer et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing
Hira Rizvi et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer
L. Gandhi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer
J. -C. Soria et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Association of high tumor mutation (TMB) with DNA damage repair (DDR) alterations and better prognosis in ovarian cancer
Wenjuan Tian et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer
Siddhartha Devarakonda et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Phase III study comparing gefitinib monotherapy (G) to combination therapy with gefitinib, carboplatin, and pemetrexed (GCP) for untreated patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009).
Atsushi Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab
David R. Gandara et al.
NATURE MEDICINE (2018)
65PDHigh tumor mutational burden (TMB) and PD-L1 have similar predictive utility in 2L+ NSCLC patients (pts) treated with anti-PD-L1 and anti-CTLA-4
B W Higgs et al.
ANNALS OF ONCOLOGY (2018)
Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy
Razvan Cristescu et al.
SCIENCE (2018)
Tumor Mutational Burden as an Independent Predictor of Response to Immunotherapy in Diverse Cancers
Aaron M. Goodman et al.
MOLECULAR CANCER THERAPEUTICS (2017)
Elements of cancer immunity and the cancer-immune set point
Daniel S. Chen et al.
NATURE (2017)
Evolution and clinical impact of co-occurring genetic alterations in advanced-stage EGFR-mutant lung cancers
Collin M. Blakely et al.
NATURE GENETICS (2017)
First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer
D. P. Carbone et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A molecular portrait of microsatellite instability across multiple cancers
Isidro Cortes-Ciriano et al.
NATURE COMMUNICATIONS (2017)
DNA Damage and Repair Biomarkers of Immunotherapy Response
Kent W. Mouw et al.
CANCER DISCOVERY (2017)
Neoantigens Generated by Individual Mutations and Their Role in Cancer Immunity and Immunotherapy
Mirjana Efremova et al.
FRONTIERS IN IMMUNOLOGY (2017)
DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma
Min Yuen Teo et al.
CLINICAL CANCER RESEARCH (2017)
Correlation of tumor mutation burden and chemotherapy outcomes in colorectal cancer
Sachin G. Pai et al.
CANCER RESEARCH (2017)
A Cross-Cancer Genetic Association Analysis of the DNA Repair and DNA Damage Signaling Pathways for Lung, Ovary, Prostate, Breast, and Colorectal Cancer
Peter M. Scarbrough et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2016)
Genomic Approaches to Understanding Response and Resistance to Immunotherapy
David A. Braun et al.
CLINICAL CANCER RESEARCH (2016)
Detection of Therapeutically Targetable Driver and Resistance Mutations in Lung Cancer Patients by Next-Generation Sequencing of Cell-Free Circulating Tumor DNA
Jeffrey C. Thompson et al.
CLINICAL CANCER RESEARCH (2016)
Predictive biomarkers for checkpoint inhibitor-based immunotherapy
Geoffrey T. Gibney et al.
LANCET ONCOLOGY (2016)
Development of immuno-oncology drugs - from CTLA4 to PD1 to the next generations
Axel Hoos
NATURE REVIEWS DRUG DISCOVERY (2016)
Correlation of DNA damage response (DDR) gene alterations with response to neoadjuvant (neo) dose-dense gemcitabine and cisplatin (ddGC) in urothelial carcinoma (UC).
Gopa Iyer et al.
JOURNAL OF CLINICAL ONCOLOGY (2016)
BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer
Caicun Zhou et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
The 2015 World Health Organization Classification of Lung Tumors Impact of Genetic, Clinical and Radiologic Advances Since the 2004 Classification
William D. Travis et al.
JOURNAL OF THORACIC ONCOLOGY (2015)
Lung cancer in never-smoker Asian females is driven by oncogenic mutations, most often involving EGFR
Sang Yun Ha et al.
Oncotarget (2015)
First-Line Crizotinib versus Chemotherapy in ALK-Positive Lung Cancer
Benjamin J. Solomon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 study
Caicun Zhou et al.
LANCET ONCOLOGY (2011)
New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1)
E. A. Eisenhauer et al.
EUROPEAN JOURNAL OF CANCER (2009)
分享论文
